RJA
LMDX

Raymond James & Associates’s LumiraDx Limited Common Shares LMDX Stock Holding History

Raymond James & Associates’s Portfolio LMDX Stock Details LMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-129,361
Closed -$8.14K – 4088
2023
Q4 		$8.14K Buy
129,361
+110,883
+600% +$12.9K ﹤0.01% 3807
2023
Q3 		$4.34K Sell
18,478
-5,500
-23% -$2.08K ﹤0.01% 3778
2023
Q2 		$11.5K Sell
23,978
-8,863
-27% -$4.61K ﹤0.01% 3804
2023
Q1 		$15.3K Buy
32,841
+2,086
+7% +$2K ﹤0.01% 3813
2022
Q4 		$27.7K Sell
30,755
-234,063
-88% -$247K ﹤0.01% 3768
2022
Q3 		$270K Buy
+264,818
New +$439K ﹤0.01% 3251

Other funds holding LMDX

GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Raymond James & Associates's LMDX Position: Q1 2024 in Review

Raymond James & Associates sold out of LumiraDx Limited Common Shares (LMDX) in Q1 2024, closing a stake of 129,361 shares — an estimated $8.14K sold.

Raymond James & Associates first reported a position in LMDX in Q3 2022 and held it in 6 quarters. The position peaked at $270K in Q3 2022. 4 funds tracked by Wall St. Rank hold LMDX as of Q1 2024.

  • Raymond James & Associates reported no remaining LumiraDx Limited Common Shares position as of Q1 2024 after selling out during the quarter.
  • Raymond James & Associates sold 129,361 LumiraDx Limited Common Shares shares in Q1 2024, an estimated $8.14K.
  • Raymond James & Associates first reported a position in LumiraDx Limited Common Shares in Q3 2022 and held it in 6 quarters.
  • Raymond James & Associates's LumiraDx Limited Common Shares position peaked at $270K in Q3 2022.
  • 4 funds tracked by Wall St. Rank held LumiraDx Limited Common Shares as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.